CORDIS
EU research results

CORDIS

English EN
Recruitment and activation of brown adipocytes as preventive and curative therapy for type 2 diabetes

Recruitment and activation of brown adipocytes as preventive and curative therapy for type 2 diabetes

Objective

The DIABAT project will employ knowledge of the function, dysfunction and physiological regulation of brown adipocytes to develop innovative therapeutic and preventive strategies for type 2 diabetes. Brown adipose tissue (BAT) is currently a worldwide recognized target to combat obesity and diabetes due to last years re-discovery of functional BAT in adult humans by several of the members of the DIABAT network (van Marken LIchtenbelt et al., N. Engl. J. Med. 360, 1500, 2009; Virtanen…, Enerbäck & Nuutila, N. Engl. J. Med. 360, 1518, 2009) along with sharp rise in insight in cellular, genetic, and regulatory mechanisms from animal studies. Therefore, the DIABAT project aims at recruiting and re-activating endogenous energy-dissipating BAT as a preventive and/or remedial measure for weight and blood sugar control in obesity-related type 2 diabetes (“diabesity”), thereby halting or preventing destruction and facilitating recovery of pancreatic beta-cells under diabetic conditions.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG

Address

Im Neuenheimer Feld 280
69120 Heidelberg

Germany

Activity type

Research Organisations

EU Contribution

€ 566 182

Administrative Contact

Ina Wiest (Dr.)

Participants (20)

Sort alphabetically

Sort by EU Contribution

Expand all

FYZIOLOGICKY USTAV AKADEMIE VED CESKE REPUBLIKY VEREJNA VYZKUMNA INSTITUCE (VVI)

Czechia

EU Contribution

€ 201 600

EVOLVA BIOTECH A/S

Denmark

EU Contribution

€ 367 184

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

France

EU Contribution

€ 493 732,56

TECHNISCHE UNIVERSITAET GRAZ

Austria

EU Contribution

€ 245 638

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

United Kingdom

EU Contribution

€ 14 682,62

UNIVERSITEIT MAASTRICHT

Netherlands

EU Contribution

€ 378 527

Maastricht Instruments

Netherlands

EU Contribution

€ 83 517

MILTENYI BIOTEC GMBH

Germany

EU Contribution

€ 386 800

STOCKHOLMS UNIVERSITET

Sweden

EU Contribution

€ 424 743

TECHNISCHE UNIVERSITAET MUENCHEN

Germany

EU Contribution

€ 197 570

UNIVERSITA POLITECNICA DELLE MARCHE

Italy

EU Contribution

€ 197 760

UNIVERSITAT DE LES ILLES BALEARS

Spain

EU Contribution

€ 211 260

KOBENHAVNS UNIVERSITET

Denmark

EU Contribution

€ 712 480

UNIVERSITE DE GENEVE

Switzerland

EU Contribution

€ 206 400

GOETEBORGS UNIVERSITET

Sweden

EU Contribution

€ 210 371

TURUN YLIOPISTO

Finland

EU Contribution

€ 349 600

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 178 005,44

EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH

Switzerland

EU Contribution

€ 297 600

UNIVERSITE DE LAUSANNE

Switzerland

EU Contribution

€ 91 200

THE UNIVERSITY OF WARWICK

United Kingdom

EU Contribution

€ 185 145,38

Project information

Grant agreement ID: 278373

Status

Closed project

  • Start date

    1 October 2011

  • End date

    30 September 2015

Funded under:

FP7-HEALTH

  • Overall budget:

    € 9 958 633,19

  • EU contribution

    € 5 999 998

Coordinated by:

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG

Germany